[We expect to deliver the Notes to investors through the book-entry delivery system of The Depository Trust Company and its direct participants, including Euroclear Bank S.A./N.V., or Euroclear, and Clearstream Banking, société anonyme, or Clearstream, on or about , 2015, which is the fifth business day following the date of this prospectus supplement. Purchasers of the Notes should note that]
[We expect to deliver the Notes to investors through the book-entry delivery system of The Depository Trust Company and its direct participants, including Euroclear Bank S.A./N.V., or Euroclear, and Clearstream Banking, société anonyme, or Clearstream, on or about , 2015, which is the fifth business day following the date of this prospectus supplement. Purchasers of the Notes should note that]
[Issued June 10, 2015 PROSPECTUS SUPPLEMENT 3,000,000 Shares China Biologic Products, Inc. Common Stock China Biologic Products, Inc. is offering 700,000 shares of its common stock. The selling stockholders identified in this prospectus supplement are offering an additional 2,300,000 shares of common stock. We will not receive any proceeds from the sale of shares by the selling stockholders. Our common]
[Issued June 10, 2015 PROSPECTUS SUPPLEMENT 3,000,000 Shares China Biologic Products, Inc. Common Stock China Biologic Products, Inc. is offering 700,000 shares of its common stock. The selling stockholders identified in this prospectus supplement are offering an additional 2,300,000 shares of common stock. We will not receive any proceeds from the sale of shares by the selling stockholders. Our common]
[PROSPECTUS SUPPLEMENT Page]
[Registration No. 333-196755 PROSPECTUS SUPPLEMENT (To Prospectus dated June 26, 2014) 2,102,484 Ordinary Shares Investing in our securities involves a high degree of risk. Please read Risk Factors beginning on page S-6 of this prospectus supplement and on page 2 of the accompanying prospectus. Per Series A Per Series B Per Ordinary Share/Total Share/ Total for Share/ Total for for]
[Registration No. 333-196755 PROSPECTUS SUPPLEMENT (To Prospectus dated June 26, 2014) 2,102,484 Ordinary Shares Investing in our securities involves a high degree of risk. Please read Risk Factors beginning on page S-6 of this prospectus supplement and on page 2 of the accompanying prospectus. Per Series A Per Series B Per Ordinary Share/Total Share/ Total for Share/ Total for for]
[Amendment No. 1 to Prospectus Supplement dated May 13, 2015 Up to $10,000,000 Ordinary Shares This amendment No. 1 to prospectus supplement (the “Amendment No.1”) is being filed solely to correct a typographical error which appear in the prospectus supplement dated May 13, 2015 (“Prospectus Supplement”) and to consistently present the increase in net tangible book value per share to]
[Amendment No. 1 to Prospectus Supplement dated May 13, 2015 Up to $10,000,000 Ordinary Shares This amendment No. 1 to prospectus supplement (the “Amendment No.1”) is being filed solely to correct a typographical error which appear in the prospectus supplement dated May 13, 2015 (“Prospectus Supplement”) and to consistently present the increase in net tangible book value per share to]
